BlockBeats News, August 20th, according to BIT (bit.com) market data, Moderna (MRNA.O) dropped by 16%, after a more than 170% surge in the previous day's close.

Earlier reports stated that the personalized mRNA cancer vaccine jointly developed by Moderna and Merck showed significant success in a Phase 3 clinical trial for high-risk melanoma. This marks the world's first mRNA cancer therapy to demonstrate effectiveness in a large-scale Phase 3 trial. Following this announcement, Moderna's stock price skyrocketed by nearly 177% in a single day.